| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
10058-F4 (10058F4; 10058 F4) is a novel potent and selective c-Myc inhibitor with potential antineoplastic activity. It specifically inhibits the protein-protein interaction of c-Myc-Max. In human acute myeloid leukemia, 10058-F4 causes cell-cycle arrest, apoptosis, and myeloid differentiation.
| Targets |
c-Myc
|
|---|---|
| ln Vitro |
10058-F4 prevents the growth of leukemic cells and the dimerization of Max and Myc. AML cells undergo apoptosis and cell-cycle arrest upon exposure to 10058-F4. AML cells are stopped at the G0/G1 phase by 10058-F4, which also upregulates the expression of CDK inhibitors p21 and p27 and downregulates c-Myc expression. In the meanwhile, 10058-F4 causes apoptosis by activating the mitochondrial pathway, which is demonstrated by the cleavage of caspase 3, 7, and 9, the release of cytoplasmic cytochrome C, the downregulation of Bcl-2, and the upregulation of Bax. Additionally, 10058-F4 induces myeloid differentiation, possibly by activating several transcription factors. Likewise, primary AML cells exhibited 10058-F4-induced apoptosis and differentiation.[1] 10058-F4 reduces intracellular levels of [alpha]-fetoprotein (AFP), inhibits the growth of HepG2 cells by lowering c-Myc protein levels, and most likely does so by upregulating p21WAF1, an inhibitor of cyclin-dependent kinase (cdk). Additionally, human telomerase reverse transcriptase (hTERT) is transcriptionally downregulated upon treatment with 10058-F4. Apart from impeding the growth of HepG2 cells, 10058-F4 also increases susceptibility to doxorubicin, 5-fluorouracil (5-FU), and cisplatin, which are common chemotherapeutic agents.[2]
|
| ln Vivo |
After a single intravenous dose, peak plasma 10058-F4 concentrations of about 300 μM are observed at 5 min and decreased to below the detection limit at 360 min. The best approximation for plasma concentration versus time data is an open, two-compartment linear model. The tissues with the highest concentrations of 10058-F4 are the kidney, liver, fat, and lung. 10058-F4 tumor peak concentrations are at least ten times lower than plasma peak concentrations. There are eight 10058-F4 metabolites found in the kidney, liver, and plasma. 10058-F4 has a terminal half-life of about one hour and a distribution volume of greater than 200 milliliters per kilogram. Following intravenous administration of 20 or 30 mg/kg 10058-F4, no discernible reduction in tumor growth is observed in the mice.[3]
|
| Cell Assay |
10058-F4 concentrations are applied in triplicate to cells plated in 96-well plates (105/mL for cell lines and 5 × 105/mL for primary leukemic cells). Each well receives 20 μL of 5 mg/mL MTT added at different times. Following three hours of incubation at 37°C, 100 μL of DMSO lysis buffer is added and the MTT medium is removed. Using a spectrophotometer with a wavelength of 570 nm, the percentage of treated cell absorbance compared to solvent control cells is used to determine the number of viable cells.
|
| Animal Protocol |
The following groups are stratified based on the C B-17 SCID mice that are bearing PC-3 human prostate tumor xenografts: vehicle control, positive control (10 mg/kg docetaxel), and 10058-F4 treatment (20 or 30 mg/kg/dose). As per our earlier research, the highest dosage of 10058-F4 that can be tolerated on this regimen is 30 mg/kg. For two weeks, mice receive intravenous treatment five days a week.Tumor volumes and body weights are measured twice a week. The second study uses C B-17 SCID mice that have been stratified into similar treatment groups based on the DU145 human androgen-independent prostate cancer xenografts. Docetaxel is given intravenously every seven days in two doses of 10 mg/kg. It is the positive control used in both efficacy studies. Calipers are used to measure tumors, and TV= L×W2/2 is the formula used to calculate tumor volumes, where L is the largest diameter of the tumor and W is the smallest diameter perpendicular to L. Mice are monitored for tumor regrowth for a minimum of one week after the last dose is administered.
|
| References |
|
| Molecular Formula |
C12H11NOS2
|
|
|---|---|---|
| Molecular Weight |
249.35
|
|
| Exact Mass |
249.03
|
|
| Elemental Analysis |
C, 57.80; H, 4.45; N, 5.62; O, 6.42; S, 25.72
|
|
| CAS # |
403811-55-2
|
|
| Related CAS # |
|
|
| Appearance |
Yellow solid powder
|
|
| SMILES |
CCC1=CC=C(C=C1)/C=C/2\C(=O)NC(=S)S2
|
|
| InChi Key |
SVXDHPADAXBMFB-JXMROGBWSA-N
|
|
| InChi Code |
InChI=1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+
|
|
| Chemical Name |
(5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0104 mL | 20.0521 mL | 40.1043 mL | |
| 5 mM | 0.8021 mL | 4.0104 mL | 8.0209 mL | |
| 10 mM | 0.4010 mL | 2.0052 mL | 4.0104 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
